[hot spot] the personnel flow of the pharmaceutical circle is alarmed, and the pre market chapter of heavyweight innovative drugs is opened!

On April 23, Pfizer China announced that after 15 years of service, Wu Xiaobin, President of Pfizer core medical Greater China and national manager of Pfizer China, left Pfizer to start a new business As soon as it happened, it attracted wide attention of the drug circle and kept guessing where it was going Today, on May 2, Baiji Shenzhou announced the appointment of Dr Wu Xiaobin as general manager and President of the company in China, which also attracted hot discussion in the industry After graduating from Xinjiang University, Wu Xiaobin, one of the "Legends" in the industry, went to Germany to study in 1982 and received his master's degree in molecular biology, biochemistry and pharmacology from knonstanz University After that, he joined the pharmaceutical industry as a pharmaceutical representative unexpectedly, which has started his career for more than 25 years He has accumulated experience in famous international large enterprises of Bayer, Wyeth and Pfizer, from pharmaceutical representative, general manager of Bayer pharmaceutical China, CEO of Wyeth pharmaceutical and CEO of Pfizer China to now general manager and President of Baiji Shenzhou China He is the first local person to serve as the head of China's multinational pharmaceutical enterprises, and is hailed as the legend of the godfather of Chinese pharmaceutical sales in the industry Wu Xiaobin's personal charm lies not only in his legendary industry experience, but also in his unique forward-looking vision and feelings as a medical person Wu Xiaobin expressed his preference for original drugs before he officially announced his resignation from Pfizer In terms of policy environment and market space, he believed that the outbreak of original drugs in China was about to come Among the original drugs, bio drugs had already stepped on the front edge of the times, so it's not surprising that he chose Baiji Shenzhou "I was impressed by the entrepreneurial spirit, rigorous attitude to science and high quality of employees of Baiji Shenzhou, as well as the sense of mission to become a global leader in the exploration, development and commercialization of innovative anti-cancer drugs," said Dr Wu Xiaobin "The future of baiji is bright, and I'm happy to be part of this truly different company." In addition, Dr Wu Xiaobin has always been adhering to his original heart, rich heart and unique feelings of the industry He has always maintained a relaxed and peaceful attitude towards his work "I have little pressure As long as I am an honest person and sleep at night, I will have the most precious freedom In this way, any goal can be achieved " This sentence was once regarded as the standard by many learners in the industry I believe that the spiritual freedom based on sincerity will create a fuller career experience for Dr Wu Xiaobin, and the future combination with Baiji Shenzhou will create more value for the pharmaceutical industry and bring more high-quality and good medicine to the public Baiji Shenzhou company - the industry "myth" pharmaceutical company Baiji Shenzhou experience has been known by the industry as strange, the company's goal is to "discover the next generation of cancer treatment drugs." Founded in 2010 by Academician Wang Xiaodong and CEO Ou Lei Qiang (Wang Xiaodong is an academician of the National Academy of Sciences, a foreign academician of the Chinese Academy of Sciences and director of the Beijing Institute of life sciences; ou leiqiang has 20 years of management and operation experience, and previously co founded and led the development of Baonuo technology, China's third largest contract research institution, with partners, and was acquired by PPD, the world's top four contract research institutions.) In 2016, Baiji was listed in the United States against the trend, and a mysterious company that had been established for five years without product listing appeared in the public view in this way In the next two years, the market value of Baiji increased six times, creating a myth Baiji Shenzhou became a unicorn in the field of biomedical innovation In the first quarter of 2018, Baiji Shenzhou made a series of big moves On January 16, Baiji Shenzhou announced a new round of stock public offering plan On January 22, it raised about $800 million, the third largest amount in the world's biotechnology field in five years In the first quarter, the market value of Baiji Shenzhou reached 56.7 billion yuan, ranking 202 among China's top 500 listed enterprises and 11 in the pharmaceutical industry, up 231 compared with the market value ranking in 2017 (in the first quarter of 2018, the market value of the top 500 companies: Hengrui HENGQIANG, Shiyao and China Bio advanced 100 billion, and Baiji Shenzhou and Taige medicine are rising strongly) the reason for such achievements lies in the rich R & D pipelines of Baiji Shenzhou and a series of strategic cooperation with the international pharmaceutical giant Xinji In terms of research and development, Baiji Shenzhou has been committed to the pursuit of innovation, and has never been stingy in the cost of research and development, and has boldly developed new drugs in the mode of "burning money" According to the 2017 performance report, the company's R & D cost is US $269.02 million (about RMB 1.7 billion), with an average growth rate of over 150% in the past three years In addition, with the rapid development of policies, innovative drugs developed locally can start clinical trials in China and around the world simultaneously, which makes the rapid development of Baiji Shenzhou At present, the company has 7 drugs in clinical stage, which are cutting-edge and hot projects in the field of global new drug research and development Three drugs have entered the late stage of clinical research and development, including the second generation Btk inhibitor zanubrutinib (bgb-3111), humanized PD-1 monoclonal antibody tislilizumab (bgb-a317), small molecule inhibitor pamiparib (bgb-290) for PARP1 and PARP2 In terms of cooperation, Baiji Shenzhou reached strategic cooperation with pharmaceutical giant Xinji in July 2017 to jointly develop and commercialize the PD-1 antibody bgb-a317 independently developed by Baiji Shenzhou to treat solid tumors And Baiji Shenzhou will take over the operation of Xinji company in China, with the exclusive authorization of products approved by Xinji company in China As a result, Baiji Shenzhou obtained about $263 million in advance and $150 million in equity investment In the future, it can also obtain milestone payments (including R & D, registration and sales) of up to $980 million and royalties for new base sales of bgb-a317 In January 2018, we also reached a cooperation with Boehringer Ingelheim Tislilizumab (bgb-a317) will be produced in the Boehringer Ingelheim biopharmaceutical production base in Shanghai, which is ready for the listing of PD-1 At this time, the high-profile PD-1 antibody tislilizumab (bgb-a317), as a potential second-line treatment for advanced non resectable or metastatic esophageal squamous cell carcinoma (ESCC), has achieved the first clinical trial in the world, bringing important good news In addition, according to drug intelligence data, (bgb-a317) is used in global phase 3 clinical trials for patients with non-small cell lung cancer and liver cancer, and phase 2 clinical trials for patients with recurrent / refractory classic Hodgkin's lymphoma and patients with urothelial cancer are also in progress in China There are also large pharmaceutical enterprises in China, such as Zhengda Tianqing, Hengrui, Baiji Shenzhou, Xinda, Jiahe, yaomingkant, Junshi, etc., which are applying for PD-1 At present, Xinda is in the lead Its listing application was undertaken by CDE on April 19, and announced on April 23 that it is planned to be included in the priority review At present, five tests of pamiparib (bgb-290) and tislilizumab have entered three phases in China, as shown in the figure below Baiji's mythical explosive power, cutting-edge strategic cooperation, solid original support and high-end talent support enable the enterprise to move forward strongly At present, although the original drug of Baiji Shenzhou has not been put on the market, under the authorization of Xinji company, Baiji Shenzhou has been selling the following products in China: atraxane ® injection paclitaxel (nano albumin particle binding type), refumex ® (lenalidomide capsule) and vedasa ® (azacytidine for injection) The company is already in the market layout for blockbuster drugs, and the creation of a strong marketing team by Dr Wu Xiaobin will be a part of it "Dr Wu Xiaobin has been successful in establishing and operating organizational structure in China Strong leadership ability enables him to build an outstanding team, bring effective treatment to patients, and bring outstanding performance to the company These will bring vital help to the development of Baiji in the next stage, "said ou Information source: Baiji Shenzhou, network information, pharmaceutical intelligence data